Developer docs
API playgroundTry for free, no card

Search company profiles

Groupe PARIMA

Full company profile

uuid000hdx5

Namestring
Groupe PARIMA
Legal namestring
Groupe PARIMA Inc.
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Groupe PARIMA is a privately held Contract Development and Manufacturing Organization (CDMO) founded in 1994 and headquartered in Montreal, Quebec. The company specializes exclusively in non-sterile pharmaceutical dosage forms — semi-solids (creams, gels, ointments, lotions, foams), liquids (oral, nasal, otic, topical), and suspensions — for global pharmaceutical clients ranging from startups to multinational pharmaceutical companies. All operations are conducted from a single 67,000 ft² (6,225 m²) GMP-compliant facility that houses manufacturing suites, temperature-controlled stability chambers, fully equipped analytical laboratories, and ten primary packaging lines, with production capacity rated at 30M+ units annually.

Technically, Groupe PARIMA operates as a vertically integrated CDMO offering formulation development (including pre-formulation studies, de novo development, deformulation, and optimization via QbD/DoE), analytical method development and validation (including IVRT using Franz diffusion cells, microbiology, and ICH stability studies), commercial-scale manufacturing with batch sizes from 5 to 4,000 kg, and primary/secondary packaging including serialization and aggregation. A Class 1 Division 1 explosion-proof manufacturing suite enables safe handling of volatile or alcohol-based formulations, and the Waters Empower 3 chromatography network underpins data integrity across GC, HPLC, UPLC, headspace, and LCMS instruments. Turn-key services encompass raw material sourcing, supplier qualification, supply chain management, cold-chain distribution, and logistics via 3PL partners.

The business model is 100% fee-for-service contract manufacturing and development with no competing product portfolio. Revenue is generated through project-based contracts for clinical and commercial batches across roughly 30+ markets and 45+ countries, with no publicly disclosed pricing. Go-to-market is enterprise sales-led, supported by participation in BIO International Convention, Bio Europe, DCAT Week, Contract Pharma Conference, and CDMO Live, plus a free 1-hour scale-up consulting offering positioned as a lead-generation tool for startup pharma clients. Regulatory standing is a core enabler — the site is favorably inspected by the FDA, EMA, Health Canada, and the Turkish Medicines and Medical Devices Agency, with mutual recognition extending coverage to Medsafe New Zealand and additional jurisdictions.

Short descriptiontext

Groupe PARIMA is a Montreal-based, founder-owned CDMO founded in 1994 that develops and manufactures non-sterile semi-solid, liquid, and suspension pharmaceutical products on a 100% fee-for-service basis for pharmaceutical clients across 45+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSaint Laurent, Canada
HQ citystring
Saint Laurent
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, non-sterile drug products, formulation development services, GMP manufacturing packaging, analytical development testing
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
Product category
Pharmaceutical CDMO Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Manufacturing Services
TypeProfessional Services
Description

Fee-for-service contract manufacturing of pharmaceutical products. The company is 100% fee-for-service and exclusively focused on contract services, helping clients meet their objectives without competing with them. Revenue is generated through manufacturing and packaging services for clinical and commercial batches.

groupeparima.com
2Pharmaceutical Development Services
TypeProfessional Services
Description

Formulation development, process development, tech transfer, and validation services. Includes pre-formulation studies, de novo development, deformulation, formulation optimization, and scale-up support.

groupeparima.com
3Analytical Testing Services
TypeProfessional Services
Description

In-house analytical laboratory services including method development, validation, transfer, quality control testing (chemistry and microbiology), and stability studies under ICH conditions.

groupeparima.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Groupe PARIMA is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures non-sterile semi-solid, liquid, and suspension drug products for oral, topical, nasal, and otic routes of administration. The company operates on a 100% fee-for-service contract basis, offering integrated services spanning formulation development, GMP-compliant manufacturing and packaging, and in-house analytical development and quality control testing. Manufacturing and packaging services support clinical and commercial batches with batch sizes ranging from 5 kg to 4,000 kg, producing up to 30 million units annually for clients across 30+ global markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 90% Right-First-Time rate for commercial batches
+3 more records
Product overview1 text field

Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO) established in 1994, offering an integrated portfolio of pharmaceutical development and manufacturing services. The company's core offerings include Formulation Development (pre-formulation, de novo development, deformulation, and optimization for semi-solids, liquids, and suspensions), Manufacturing & Packaging (GMP-compliant production with batch sizes from 5 to 4,000 kg), and Analytical Development (in-house laboratory for method development, validation, QC testing, and stability studies). Supporting services include Scale-Up Consulting (1-hour free consulting for startups) and ESG+ (sustainability framework). The company specializes in non-sterile dosage forms across semi-solids (creams, gels, ointments, lotions, foams), liquids (oral, nasal, otic, topical), and suspensions. Products are manufactured for over 30 markets globally from the company's 67,000 ft² facility in Montreal, Canada.

Product and service4 records
1Formulation Development
CategoryPharmaceutical Development Services
Description

Comprehensive formulation development services for non-sterile liquids, semi-solids, and suspensions, including pre-formulation studies, de novo development, deformulation, and formulation optimization using QbD and DoE methodologies. Designed for pharmaceutical companies needing expert support across the development lifecycle.

2Manufacturing & Packaging
CategoryContract Manufacturing & Packaging
Description

GMP-compliant pharmaceutical manufacturing and packaging services for non-sterile drug products, including semi-solids (creams, gels, ointments, lotions), liquids, and suspensions, with batch sizes from 5 to 4,000 kg. Turn-key supply chain solutions including serialization and aggregation for global regulatory compliance. Serves pharmaceutical companies requiring commercial-scale production.

3Analytical Development
CategoryAnalytical Testing Services
Description

In-house analytical laboratory services including method development, validation, transfer, forced degradation studies, IVRT testing, chemistry and microbiology quality control, and ICH-compliant stability studies. All chromatography performed on Waters Empower 3 network ensuring data integrity for regulatory traceability. Supports pharmaceutical companies with regulatory submissions and routine quality control.

4Scale-Up Consulting
CategoryConsulting Services
Description

One-hour free consulting service for startup pharma companies to navigate scaling from small development batches (as little as 2 kg) to GMP-compliant clinical trial production and commercial scale, including QbD and DoE guidance. Designed to support early-stage pharmaceutical companies with scale-up strategy.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hovione is a mid-sized CDMO specializing in API synthesis, particle engineering, and drug product manufacturing including semi-solids and oral dosage forms. Comparable as a similarly-sized specialty CDMO with strong technical expertise and global pharmaceutical customer base.

2Tapemark
TypeDirect peer
Description

Tapemark is a contract manufacturer specializing in transdermal patches, topical, and oral dissolvable films, with development and commercial manufacturing services. Comparable as a mid-sized specialty CDMO serving pharmaceutical clients with complex non-sterile dosage forms.

TypeBroad incumbent
Description

PCI Pharma Services is a global CDMO providing drug development, manufacturing, and packaging services across multiple dosage forms including liquids and semi-solids. Broader than Groupe PARIMA with sterile capabilities, but overlaps in commercial manufacturing and packaging for similar pharmaceutical customers.

TypeBroad incumbent
Description

Catalent is one of the largest global CDMOs offering development and manufacturing across oral, sterile, biologic, and inhalation dosage forms. Broader and larger than Groupe PARIMA, but overlaps significantly in oral liquids, semi-solids, and softgel manufacturing for similar pharmaceutical customers.

TypeDirect peer
Description

Cambrex (now owned by Permira) is a CDMO providing active pharmaceutical ingredient development and manufacturing, including small-molecule APIs and finished dosage forms. Comparable as a similarly-sized specialty CDMO serving pharma clients with development through commercial manufacturing capabilities.

TypeDirect peer
Description

CoreRx is a CDMO offering formulation development, analytical services, and commercial manufacturing for oral solids, liquids, and semi-solids. Comparable given similar focus on small to mid-sized pharma customers and integrated development-to-commercial service offerings.

TypeDirect peer
Description

Adare Pharma Solutions is a specialty CDMO with deep expertise in oral solid and semi-solid dosage forms, serving similar pharmaceutical customers with formulation development and commercial manufacturing services. Directly comparable as a mid-sized non-sterile-focused CDMO targeting similar therapeutic areas and dosage forms.

TypeBroad incumbent
Description

Thermo Fisher Scientific acquired Patheon to form a major CDMO franchise offering API, oral solid, sterile, and biologic drug product services globally. Overlaps with Groupe PARIMA in oral liquids, semi-solids, and commercial manufacturing but at vastly greater scale and service breadth.

TypeDirect peer
Description

Halo Pharma is a CDMO specializing in non-sterile liquid, semi-solid, and oral solid dose manufacturing for small to mid-sized pharmaceutical companies. Highly comparable given similar dosage-form focus, customer profile, and turn-key development-to-commercial service model.

TypeBroad incumbent
Description

Aenova is a European-based CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing for pharmaceutical and consumer health customers. Comparable as a mid-to-large CDMO serving similar dosage forms and customer segments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Groupe PARIMA

Pharmaceutical CDMO Servicesgroupeparima.com

Groupe PARIMA is a Montreal-based, founder-owned CDMO founded in 1994 that develops and manufactures non-sterile semi-solid, liquid, and suspension pharmaceutical products on a 100% fee-for-service basis for pharmaceutical clients across 45+ countries.

What Groupe PARIMA does

Groupe PARIMA is a privately held Contract Development and Manufacturing Organization (CDMO) founded in 1994 and headquartered in Montreal, Quebec. The company specializes exclusively in non-sterile pharmaceutical dosage forms — semi-solids (creams, gels, ointments, lotions, foams), liquids (oral, nasal, otic, topical), and suspensions — for global pharmaceutical clients ranging from startups to multinational pharmaceutical companies. All operations are conducted from a single 67,000 ft² (6,225 m²) GMP-compliant facility that houses manufacturing suites, temperature-controlled stability chambers, fully equipped analytical laboratories, and ten primary packaging lines, with production capacity rated at 30M+ units annually.

Technically, Groupe PARIMA operates as a vertically integrated CDMO offering formulation development (including pre-formulation studies, de novo development, deformulation, and optimization via QbD/DoE), analytical method development and validation (including IVRT using Franz diffusion cells, microbiology, and ICH stability studies), commercial-scale manufacturing with batch sizes from 5 to 4,000 kg, and primary/secondary packaging including serialization and aggregation. A Class 1 Division 1 explosion-proof manufacturing suite enables safe handling of volatile or alcohol-based formulations, and the Waters Empower 3 chromatography network underpins data integrity across GC, HPLC, UPLC, headspace, and LCMS instruments. Turn-key services encompass raw material sourcing, supplier qualification, supply chain management, cold-chain distribution, and logistics via 3PL partners.

The business model is 100% fee-for-service contract manufacturing and development with no competing product portfolio. Revenue is generated through project-based contracts for clinical and commercial batches across roughly 30+ markets and 45+ countries, with no publicly disclosed pricing. Go-to-market is enterprise sales-led, supported by participation in BIO International Convention, Bio Europe, DCAT Week, Contract Pharma Conference, and CDMO Live, plus a free 1-hour scale-up consulting offering positioned as a lead-generation tool for startup pharma clients. Regulatory standing is a core enabler — the site is favorably inspected by the FDA, EMA, Health Canada, and the Turkish Medicines and Medical Devices Agency, with mutual recognition extending coverage to Medsafe New Zealand and additional jurisdictions.

Groupe PARIMA firmographics

Firmographics
Name
Groupe PARIMA
Legal name
Groupe PARIMA Inc.
Website
https://groupeparima.com
Company type
Private
Founded year
1994
Operating status
Operating
Headcount range
51–100 employees
Short description
Groupe PARIMA is a Montreal-based, founder-owned CDMO founded in 1994 that develops and manufactures non-sterile semi-solid, liquid, and suspension pharmaceutical products on a 100% fee-for-service basis for pharmaceutical clients across 45+ countries.
Ownership category
akta.pro rank

Groupe PARIMA industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical contract manufacturing
  • Non-sterile drug products
  • Formulation development services
  • GMP manufacturing packaging
  • Analytical development testing

Where Groupe PARIMA is headquartered

Location

Headquarters

HQ city
Saint Laurent
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Groupe PARIMA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: Fee-for-service contract manufacturing of pharmaceutical products. The company is 100% fee-for-service and exclusively focused on contract services, helping clients meet their objectives without competing with them. Revenue is generated through manufacturing and packaging services for clinical and commercial batches.
  2. Pharmaceutical Development Services: Formulation development, process development, tech transfer, and validation services. Includes pre-formulation studies, de novo development, deformulation, formulation optimization, and scale-up support.
  3. Analytical Testing Services: In-house analytical laboratory services including method development, validation, transfer, quality control testing (chemistry and microbiology), and stability studies under ICH conditions.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Groupe PARIMA product offering

Product offering

Core offering

Groupe PARIMA is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures non-sterile semi-solid, liquid, and suspension drug products for oral, topical, nasal, and otic routes of administration. The company operates on a 100% fee-for-service contract basis, offering integrated services spanning formulation development, GMP-compliant manufacturing and packaging, and in-house analytical development and quality control testing. Manufacturing and packaging services support clinical and commercial batches with batch sizes ranging from 5 kg to 4,000 kg, producing up to 30 million units annually for clients across 30+ global markets.

Product overview

Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO) established in 1994, offering an integrated portfolio of pharmaceutical development and manufacturing services. The company's core offerings include Formulation Development (pre-formulation, de novo development, deformulation, and optimization for semi-solids, liquids, and suspensions), Manufacturing & Packaging (GMP-compliant production with batch sizes from 5 to 4,000 kg), and Analytical Development (in-house laboratory for method development, validation, QC testing, and stability studies). Supporting services include Scale-Up Consulting (1-hour free consulting for startups) and ESG+ (sustainability framework). The company specializes in non-sterile dosage forms across semi-solids (creams, gels, ointments, lotions, foams), liquids (oral, nasal, otic, topical), and suspensions. Products are manufactured for over 30 markets globally from the company's 67,000 ft² facility in Montreal, Canada.

Differentiator

Problem solved

Functional benefit

Products and services

  • Formulation Development Comprehensive formulation development services for non-sterile liquids, semi-solids, and suspensions, including pre-formulation studies, de novo development, deformulation, and formulation optimization using QbD and DoE methodologies. Designed for pharmaceutical companies needing expert support across the development lifecycle.
  • Manufacturing & Packaging GMP-compliant pharmaceutical manufacturing and packaging services for non-sterile drug products, including semi-solids (creams, gels, ointments, lotions), liquids, and suspensions, with batch sizes from 5 to 4,000 kg. Turn-key supply chain solutions including serialization and aggregation for global regulatory compliance. Serves pharmaceutical companies requiring commercial-scale production.
  • Analytical Development In-house analytical laboratory services including method development, validation, transfer, forced degradation studies, IVRT testing, chemistry and microbiology quality control, and ICH-compliant stability studies. All chromatography performed on Waters Empower 3 network ensuring data integrity for regulatory traceability. Supports pharmaceutical companies with regulatory submissions and routine quality control.
  • Scale-Up Consulting One-hour free consulting service for startup pharma companies to navigate scaling from small development batches (as little as 2 kg) to GMP-compliant clinical trial production and commercial scale, including QbD and DoE guidance. Designed to support early-stage pharmaceutical companies with scale-up strategy.

Quantifiable outcome

  • 90% Right-First-Time rate for commercial batches
  • +3 more outcomes

Companies that use Groupe PARIMA

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Groupe PARIMA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Groupe PARIMA partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Groupe PARIMA competitors and assessment

Company assessment

Direct peers

  • Hovione: Hovione is a mid-sized CDMO specializing in API synthesis, particle engineering, and drug product manufacturing including semi-solids and oral dosage forms. Comparable as a similarly-sized specialty CDMO with strong technical expertise and global pharmaceutical customer base.
  • Tapemark: Tapemark is a contract manufacturer specializing in transdermal patches, topical, and oral dissolvable films, with development and commercial manufacturing services. Comparable as a mid-sized specialty CDMO serving pharmaceutical clients with complex non-sterile dosage forms.
  • Cambrex: Cambrex (now owned by Permira) is a CDMO providing active pharmaceutical ingredient development and manufacturing, including small-molecule APIs and finished dosage forms. Comparable as a similarly-sized specialty CDMO serving pharma clients with development through commercial manufacturing capabilities.
  • CoreRx: CoreRx is a CDMO offering formulation development, analytical services, and commercial manufacturing for oral solids, liquids, and semi-solids. Comparable given similar focus on small to mid-sized pharma customers and integrated development-to-commercial service offerings.
  • Adare Pharma Solutions: Adare Pharma Solutions is a specialty CDMO with deep expertise in oral solid and semi-solid dosage forms, serving similar pharmaceutical customers with formulation development and commercial manufacturing services. Directly comparable as a mid-sized non-sterile-focused CDMO targeting similar therapeutic areas and dosage forms.
  • Halo Pharma: Halo Pharma is a CDMO specializing in non-sterile liquid, semi-solid, and oral solid dose manufacturing for small to mid-sized pharmaceutical companies. Highly comparable given similar dosage-form focus, customer profile, and turn-key development-to-commercial service model.

Broad incumbents

  • PCI Pharma Services: PCI Pharma Services is a global CDMO providing drug development, manufacturing, and packaging services across multiple dosage forms including liquids and semi-solids. Broader than Groupe PARIMA with sterile capabilities, but overlaps in commercial manufacturing and packaging for similar pharmaceutical customers.
  • Catalent: Catalent is one of the largest global CDMOs offering development and manufacturing across oral, sterile, biologic, and inhalation dosage forms. Broader and larger than Groupe PARIMA, but overlaps significantly in oral liquids, semi-solids, and softgel manufacturing for similar pharmaceutical customers.
  • Thermo Fisher Scientific (Patheon): Thermo Fisher Scientific acquired Patheon to form a major CDMO franchise offering API, oral solid, sterile, and biologic drug product services globally. Overlaps with Groupe PARIMA in oral liquids, semi-solids, and commercial manufacturing but at vastly greater scale and service breadth.
  • Aenova Group: Aenova is a European-based CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing for pharmaceutical and consumer health customers. Comparable as a mid-to-large CDMO serving similar dosage forms and customer segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Groupe PARIMA social profiles

Digital presence

Groupe PARIMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Groupe PARIMA leadership team

Management profile

Number of profiles

Profiles5 records

Groupe PARIMA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Groupe PARIMA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Groupe PARIMA

What does Groupe PARIMA do?

Groupe PARIMA is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that develops and manufactures non-sterile semi-solid, liquid, and suspension drug products for oral, topical, nasal, and otic routes of administration. The company operates on a 100% fee-for-service contract basis, offering integrated services spanning formulation development, GMP-compliant manufacturing and packaging, and in-house analytical development and quality control testing. Manufacturing and packaging services support clinical and commercial batches with batch sizes ranging from 5 kg to 4,000 kg, producing up to 30 million units annually for clients across 30+ global markets.

Is Groupe PARIMA a public or private company?

Groupe PARIMA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Groupe PARIMA founded?

Groupe PARIMA was founded in 1994. It employs 51 to 100 people.

Where is Groupe PARIMA based?

Groupe PARIMA is headquartered in Saint Laurent, Canada, in the North America region.

How does Groupe PARIMA make money?

Three revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are pharmaceutical Development Services and analytical Testing Services.

Who are Groupe PARIMA's main competitors?

Direct peers on record are Hovione, Tapemark, Cambrex, CoreRx, Adare Pharma Solutions and Halo Pharma. Broad incumbents are PCI Pharma Services, Catalent, Thermo Fisher Scientific (Patheon) and Aenova Group.

Does Groupe PARIMA have an API?

No public API is recorded for Groupe PARIMA.

What industry is Groupe PARIMA in?

Groupe PARIMA's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 3254.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales